Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-23-010149
Filing Date
2023-05-18
Accepted
2023-05-17 20:00:12
Documents
14
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A tbph-20230331x10qa.htm   iXBRL 10-Q/A 95015
2 EX-31.1 tbph-20230331xex31d1.htm EX-31.1 7388
3 EX-31.2 tbph-20230331xex31d2.htm EX-31.2 6883
  Complete submission text file 0001558370-23-010149.txt   266258

Data Files

Seq Description Document Type Size
4 EX-101.SCH tbph-20230331.xsd EX-101.SCH 3138
5 EX-101.LAB tbph-20230331_lab.xml EX-101.LAB 20442
6 EX-101.PRE tbph-20230331_pre.xml EX-101.PRE 12871
8 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20230331x10qa_htm.xml XML 6596
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-36033 | Film No.: 23933449
SIC: 2834 Pharmaceutical Preparations